Nurix Therapeutics, INC. 8-K Filing
Ticker: NRIX · Form: 8-K · Filed: Nov 10, 2025 · CIK: 1549595
Sentiment: neutral
Filing Stats: 995 words · 4 min read · ~3 pages · Grade level 11.5 · Accepted 2025-11-10 07:15:02
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share NRIX Nasdaq Global
- $50,000 — will receive a pro rata portion of the $50,000 annual retainer for service as a direct
- $7,500 — 30, 2025, and a pro rata portion of the $7,500 annual retainer for service as a member
Filing Documents
- nrix-20251106.htm (8-K) — 31KB
- a251110nurixprbodappointme.htm (EX-99.1) — 13KB
- 0001549595-25-000117.txt ( ) — 167KB
- nrix-20251106.xsd (EX-101.SCH) — 2KB
- nrix-20251106_lab.xml (EX-101.LAB) — 22KB
- nrix-20251106_pre.xml (EX-101.PRE) — 13KB
- nrix-20251106_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are filed herewith and this list is intended to constitute the exhibit index: Exhibit No. Exhibit Title or Description 99.1 Press Release dated November 10 , 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NURIX THERAPEUTICS, INC. Date: November 10, 2025 By: /s/ Christine Ring Christine Ring, Ph.D., J.D. Chief Legal Officer 3